These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 29171057)
1. Real-World Evidence, Public Participation, and the FDA. Schwartz JL Hastings Cent Rep; 2017 Nov; 47(6):7-8. PubMed ID: 29171057 [TBL] [Abstract][Full Text] [Related]
2. Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015. Zhang AD; Schwartz JL; Ross JS Milbank Q; 2019 Sep; 97(3):796-819. PubMed ID: 31304643 [TBL] [Abstract][Full Text] [Related]
3. The Food and Drug Administration advisory committees and panels: how they are applied to the drug regulatory process. Ciociola AA; Karlstadt RG; Pambianco DJ; Woods KL; Ehrenpreis ED; Am J Gastroenterol; 2014 Oct; 109(10):1508-12. PubMed ID: 25001252 [TBL] [Abstract][Full Text] [Related]
5. Association of Advisory Committee Votes With US Food and Drug Administration Decision-Making on Prescription Drugs, 2010-2021. Daval CJR; Teng TW; Russo M; Kesselheim AS JAMA Health Forum; 2023 Jul; 4(7):e231718. PubMed ID: 37418270 [TBL] [Abstract][Full Text] [Related]
6. The history and contemporary challenges of the US Food and Drug Administration. Borchers AT; Hagie F; Keen CL; Gershwin ME Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043 [TBL] [Abstract][Full Text] [Related]
7. The US Food and drug administration: drug information resource for formulary recommendations. Marchand HC; Ros BJ; Fine AM; Kremzner ME J Manag Care Pharm; 2012; 18(9):713-8. PubMed ID: 23206214 [TBL] [Abstract][Full Text] [Related]
8. Revisiting financial conflicts of interest in FDA advisory committees. Pham-Kanter G Milbank Q; 2014 Sep; 92(3):446-70. PubMed ID: 25199895 [TBL] [Abstract][Full Text] [Related]
9. The FDA and drug safety: a proposal for sweeping changes. Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825 [TBL] [Abstract][Full Text] [Related]
10. The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics. Klonoff DC J Diabetes Sci Technol; 2020 Mar; 14(2):345-349. PubMed ID: 30862182 [TBL] [Abstract][Full Text] [Related]
11. The Role of Real-World Evidence in FDA-Approved New Drug and Biologics License Applications. Purpura CA; Garry EM; Honig N; Case A; Rassen JA Clin Pharmacol Ther; 2022 Jan; 111(1):135-144. PubMed ID: 34726771 [TBL] [Abstract][Full Text] [Related]
12. How drugs are developed and approved by the FDA: current process and future directions. Ciociola AA; Cohen LB; Kulkarni P; Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999 [TBL] [Abstract][Full Text] [Related]
14. Women's health and the FDA. Wood SF N Engl J Med; 2005 Oct; 353(16):1650-1. PubMed ID: 16236734 [No Abstract] [Full Text] [Related]
15. New FDA Center May Speed Approval Process. Cancer Discov; 2016 Sep; 6(9):OF5. PubMed ID: 27417310 [TBL] [Abstract][Full Text] [Related]
16. Modernizing the FDA: an incremental revolution. Merrill RA Health Aff (Millwood); 1999; 18(2):96-111. PubMed ID: 10091437 [TBL] [Abstract][Full Text] [Related]
17. The Prescription Drug User Fee Act: Much More Than User Fees. Mitchell AP; Trivedi NU; Bach PB Med Care; 2022 Apr; 60(4):287-293. PubMed ID: 35149663 [TBL] [Abstract][Full Text] [Related]